Clinical Trial Update: Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rechallenge with panitumumab guided by RAS dynamic resistance in colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Fondazione del Piemonte per l'Oncologia | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED